skip to main content

Press Releases Archive

March 2, 2020

Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation

Download
February 12, 2020

Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA

Download
February 6, 2020

Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020

Download
January 9, 2020

Prevail Therapeutics Provides PR001 Program Update

Download
December 26, 2019

Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease

Download
December 16, 2019

Prevail Therapeutics Announces FDA Orphan Drug Designation Granted to PR006 for the Treatment of Patients with Frontotemporal Dementia with a GRN Mutation

Download
November 12, 2019

Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

Download
October 8, 2019

Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail’s Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases

Download

You are now leaving prevailtherapeutics.com

You've clicked on a link for a third-party site, which Prevail Therapeutics does not control, influence, or endorse. Prevail is not responsible for any content on this third-party site, including the privacy policy. Click "Continue" to leave or "Go Back" to return to prevailtherapeutics.com

Continue
Top